Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
27.10.2013 12:09:33

Medgenics Announces Positive Data With Second-Generation Viral Vectors

(RTTNews) - Medgenics Inc. (MDGN, MEDU.L, MEDG.L) announced that new, positive data on the Company's second-generation viral vectors were highlighted in a poster presentation at the European Society of Gene and Cell Therapy Congress.

According to the company, the new study showed that the Company's second-generation gene therapy vectors provided substantial improvements in levels and durability of therapeutic protein secretion in vitro and in vivo. In addition, the new vectors incorporated improvements in surgical technique, including co-administration of Depo-Medrol (methylprednisolone acetate) on implantation.

More specifically, when Depo-Medrol was applied to second generation vectors, animals serum hEPO levels remained 40-50 fold higher for over 100 days post implantation when compared to first generation vector with no Depo-Medrol.

The company noted that it plans to initiate human trials with a Biopump containing the second generation viral vector and new implantation protocol in the first half of 2014.

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!